3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Breast Neoplasms
54
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Neoplasm Metastasis
4
Sarcoma, Ewing
3
Neoplasms
3
Medulloblastoma
3
Lymphoma, Non-Hodgkin
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Astrocytoma
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Osteosarcoma
2
Oligodendroglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Lymphoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioblastoma
2
Ependymoma
2
Colonic Neoplasms
2
Xanthogranuloma, Juvenile
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Interventions
Sunitinib
16
Imatinib Mesylate
13
nilotinib
8
ripretinib
4
regorafenib
4
avapritinib
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
pembrolizumab
2
Bevacizumab
2
trametinib
1
tinostamustine
1
spartalizumab
1
romidepsin
1
ponatinib
1
pazopanib
1
palbociclib
1
olaratumab
1
guadecitabine
1
ferric carboxymaltose
1
epacadostat
1
dabrafenib
1
cediranib
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sorafenib
1
STA 9090
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Stromal Tumors
×
palbociclib
×
Clear all
NCT01907607
2025-08-24
CYCLIGIST
Institut Bergonié
Phase 2
Completed
29 enrolled
8 charts